Arvinas Inc (NASDAQ:ARVN) is on the cusp of a major transition with its first pivotal data readout expected by the end of 2024 or early 2025, which could lead to its first new drug application.

Barclays analyst Peter Lawson maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) today and set a price target of $48.00. The company’s shares closed yesterday at $27.66.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

As of 10:10 AM EST. Market Open. NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on ...

Arvinas Holding Company ( (ARVN)) has realeased its Q3 earnings. Here is a breakdown of the information Arvinas Holding Company presented to its investors. Arvinas, Inc. (Nasdaq: ARVN ...

Despite past poor performance, recent positive data and a strong cash balance make ARVN a cautiously optimistic investment ahead of upcoming phase 3 data. Financially, Arvinas has a market cap of ...

Oppenheimer has recently reiterated Arvinas Inc (ARVN) stock to Outperform rating ... reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 3.16, comparing the ...

In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against other best small-cap stocks to buy according to analysts. During the third quarter of 2024 ...

So, I’ve found some peace lately by curling up with a good book. Amazon recently announced a whole slew of new Kindle devices, and I was immediately intrigued. The basic Kindle model is great ...

Users will be able to see book covers and interior pictures in color, and add highlights in color. The display is 7 inches, about the same size as Amazon’s black-and-white Kindle Paperwhite device.